Stakeholders with the goal of advancing interest in value-based contracts should consider taking a slower, more concentrated approach to assuage legal worries, attendees of a recent Academy of Managed Care Pharmacy (AMCP) Partnership Forum suggested.
Health care leaders during the event hosted in Baltimore, Maryland, said setting a threshold for risk tolerance and attracting interest from top brass is a significant component to driving change toward value-based models, according to an AMCP release.
“Nowhere is the potential and challenge of value-based care more evident than in integrated delivery networks,” AMCP CEO Susan Cantrell said. “By their very design, IDNs have the necessary infrastructure in place to capture data on whether a patient or group of patients obtained a desired therapeutic outcome through an intervention. In other words, IDNs collect the data necessary to determine value in care.”
Concerns addressed at the event include:
- How value-based care is currently delivered in IDNs;
- Opportunities and barriers to implementing pharmaceutical value-based agreements; and
- Opportunities for managed care organizations, accountable care organizations and IDNs to collaborate to drive improvements in health care outcomes.